atezolizumab,vinorelbine
roche
['ipsos', 'nsclc', 'atezo', 'sclc']
#esmo22 pts with nsclc ineligible for first-line platinum-doublet chemotherapy due to poor ps ( 2) or comorbidities in patients aged 70 years derive benefit from atezo monotherapy. ipsos trial show an interesting option for vulnerable patients. 
Italian Group of Geriatric Oncology